Today's call is being recorded. At this time, I would like to turn the call over to Francesca DeMartino, chief investor relations officer and senior vice president. Please go ahead, ma'am.Francesca ...

Pfizer in a statement said it was pleased Do No Harm had decided to voluntarily dismiss the case, which the company said had no merit. The New York-based company changed the program's criteria in ...

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $32.00. The company’s shares closed yesterday at $26.91.

Activist Starboard Value did not nominate any directors to Pfizer’s (PFE) board ahead of a January 25 deadline for the company’s annual meeting in April, Damian Garde and Crystal Tse of ...

In a world of wild talk and fake news, help us stand up for the facts.

Pfizer and GSK vaccines will now be required to carry warnings that they may be tied to an increased risk of a rare neurological side effect. © 2024 Fortune Media IP ...

Jan 13 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive ...

Pfizer subsidiary Biohaven allegedly gave physicians speaker honoraria and meals at high-end restaurants to induce them to prescribe Nurtec. Healthcare lease accounting insights: How two organizations ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I think we did significant transformative changes in Pfizer.” ...

Pfizer saved $4 billion, plans $1.5 billion more in margin improvements, and issued $7 billion in dividends in nine months. Acquisitions are projected to offset $17 billion-18 billion in revenue ...

Stanley Goldfarb, Do No Harm's chair, in a statement said it was pleased the court "reversed course and correctly recognized our right to protect our members in the district court." Pfizer in a ...

NEW YORK (Reuters) - Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider trading settlement involving billionaire Steven A.